PMID- 12071078
OWN - NLM
STAT- MEDLINE
DCOM- 20021001
LR  - 20201208
IS  - 1661-8157 (Print)
IS  - 1661-8157 (Linking)
VI  - 91
IP  - 18
DP  - 2002 May 1
TI  - [Helicobacter pylori--2002].
PG  - 773-8
AB  - Treatment recommendations for H. pylori infection are peptic ulcer disease, MALT 
      lymphoma, atrophic gastritis and following gastric cancer resection as well as 
      first degree relatives of gastric cancer patients. Advisable situations are 
      functional dyspepsia, before introduction of NSAID's or intended long-term 
      proton-pump inhibitor treatment. It is thought that eradication therapy is not 
      associated with gastro-esophageal reflux disease and does not enhance NSAID 
      induced peptic ulcer healing. Therapy should be given as a package which 
      considers first and second line eradication therapies together; in uncomplicated 
      duodenal ulcer patients, eradication therapy does not need to be followed by 
      further antisecretory treatment. First line therapy should be with triple therapy 
      using a proton pump inhibitor (PPI), combined with clarithromycin and 
      amoxycilline or metronidazole. Second-line therapy should use a quadruple therapy 
      with a PPI, bismuth, metronidazole and tetracycline. Where bismuth is not 
      available, second line therapy should be with a PPI triple therapy. If second 
      line quadruple therapy fails in primary care, patients should be referred to the 
      specialist and handled on a case by case basis. Successful eradication should 
      always be confirmed by urea breath test (UBT), or endoscopy-based tests if 
      endoscopy is clinically indicated. Stool antigen test is the alternative if UBT 
      is not available. A 'test and treat' approach based on non-invasive testing can 
      be offered to adult patients presenting in primary care with persistent dyspepsia 
      under the age of 45 years (the age cut-off may vary locally), having excluded 
      those with predominantly gastroesophageal reflux disease (GERD) symptoms, NSAID 
      users, and patients with alarm symptoms.
FAU - Treiber, G
AU  - Treiber G
AD  - Klinik fur Gastroenterologie/Hepatologie/Infektiologie, 
      Otto-von-Guericke-Universitat Magdeburg.
FAU - Malfertheiner, P
AU  - Malfertheiner P
LA  - ger
PT  - Journal Article
TT  - Helicobacter pylori--2002.
PL  - Switzerland
TA  - Praxis (Bern 1994)
JT  - Praxis
JID - 101468093
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - *Anti-Bacterial Agents
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Drug Therapy, Combination/*therapeutic use
MH  - Helicobacter Infections/diagnosis/*drug therapy
MH  - *Helicobacter pylori/drug effects
MH  - Humans
MH  - *Proton Pump Inhibitors
MH  - Stomach Diseases/diagnosis/*drug therapy
EDAT- 2002/06/20 10:00
MHDA- 2002/10/03 04:00
CRDT- 2002/06/20 10:00
PHST- 2002/06/20 10:00 [pubmed]
PHST- 2002/10/03 04:00 [medline]
PHST- 2002/06/20 10:00 [entrez]
AID - 10.1024/0369-8394.91.18.773 [doi]
PST - ppublish
SO  - Praxis (Bern 1994). 2002 May 1;91(18):773-8. doi: 10.1024/0369-8394.91.18.773.